Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

Introducing EVRENZO

  • The HIF pathway

    The HIF (hypoxia inducible factor) pathway plays a central role in erythropoiesis.1,2

    The HIF pathway is the physiological mechanism by which the body responds to low oxygen conditions, such as those experienced at high altitude.

    2_1_HIF mechanism_GIF_CKD

    Activation of the HIF-pathway leads to transcription of genes involved in iron (Fe) turnover and the production of Erythropoietin (EPO) resulting in increased red blood cell count (RBC) / haemoglobin (Hb)

    The HIF pathway affects all the key components of erythropoiesis:1
    • Increases erythropoietin (EPO) production
    • Suppresses hepcidin production
    • Increases iron absorption, transport and mobilisation

    The HIF pathway is critically important to oxygen sensing3

    Under normoxic conditions, the HIF pathway is not activated: the HIF-α subunit is rapidly degraded via HIF prolyl-hydroxylase (HIF-PH) in the presence of oxygen:3

    Normoxic conditions

    gene_transcription

    Under hypoxic conditions, the HIF pathway is activated: the HIF-α subunit is not degraded and dimerises with the HIF-β subunit inducing the transcription and translation of target hypoxia response genes involved in erythropoiesis, including:3-5

    evrenzo-three

    In CKD, oxygen sensing via HIF is disrupted, and this contributes to the development of anaemia.6

    A unique strategy to mimic the physiological response to hypoxia is to inhibit HIF-PH, facilitating the accumulation of HIF-α and the resulting induction of hypoxia response genes.1

    CKD, chronic kidney disease; HIF, hypoxia-inducible factor; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; EPO, erythropoietin.

    References

    • Locatelli F et al. Am J Nephrol. 2017;45:187-199.
    • Koury MJ, Haase VH. Nat Rev Nephrol. 2015;11:394–410.
    • Haase VH. Hemodial Int. 2017;21:S110–S124.
    • Biggar P, Gheun-Ho K. Kidney Res Clin Pract. 2017;36:209–223.
    • Del Vecchio L, Locatelli F. Expert Opin Investig Drugs. 2018;27:613–621.
    • Guedes M et al. Kidney360. 2020;1(8):855-62.

  • EVRENZO: a first-in-class treatment1

    EVRENZO is a HIF-PH inhibitor, a class of drug with an innovative mechanism of action.2

    EVRENZO mimics the body’s natural response to hypoxia by activating the HIF pathway2,3

    Mimicking hypoxia

    mimicking_hypoxia

    EVRENZO inhibits HIF-PH, thus preventing breakdown of HIF-α and activating the HIF pathway2,3

    This induces transcription and translation of genes involved in erythropoiesis2,3

    HIF-PH inhibitors induce activation of the genes responsible for erythropoiesis, mimicking a hypoxic state.3

    EVRENZO reduces hepcidin levels and improves iron bioavailability3

    Through the inhibition of HIF-PH, EVRENZO stimulates a coordinated erythropoietic response that not only increases erythropoietin (EPO) levels, but also increases iron mobilisation, as well as helping to overcome the effects of inflammation by suppressing hepcidin.3

    enterocyte

    See how EVRENZO works

    EVRENZO Mechanism of action

    EVRENZO is indicated for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)3

    CKD, chronic kidney disease; EPO, erythropoietin; HIF, hypoxia-inducible factor; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase.

    References

    • Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.
    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.
    • EVRENZO SmPC.
    • Haase VH. Hemodial Int. 2017;21:S110–S124.

  • EVRENZO promotes a coordinated erythropoietic response1-3

    By inhibiting HIF-PH, EVRENZO stimulates a coordinated erythropoietic response that:1,2

    Introducing_evrenzo1

    Hb, haemoglobin; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; IV, intravenous; RBC, red blood cell.

    References

    • EVRENZO SmPC.
    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.
    • Locatelli F et al. Am J Nephrol. 2017;45:187-199.

  • The place of EVRENZO in management of anaemia of CKD

    EVRENZO has the potential to change the clinical management of anaemia of CKD.1

    Instead of treating the conditon as a deficiency of EPO or iron, EVRENZO addresses multiple factors that contribute to anaemia.1

    Targeting the HIF pathway with HIF-PHIs may offer a comprehensive and physiological approach to the management of anaemia of CKD.2

    EVRENZO helps patients with anaemia of CKD:

    • To achieve and maintain their target Hb levels3
    • With a reduced use of IV iron compared to ESA3
    • And is orally administered three times weekly3,4

    EVRENZO (roxadustat) is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD)3

    EVRENZO is contraindicated in the following conditions:
    -Hypersensitivity to active substance, peanut, soya or any of the excipients
    -Third trimester of pregnancy
    -Breastfeeding

    CKD, chronic kidney disease; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; HIF, hypoxia-inducible factor; HIF-PHI, hypoxia-inducible factor prolyl-hydroxylase inhibitor; IV, intravenous; TIW, three times weekly.

    References

    • Del Vecchio L, LocateIIi F. Expert Opin Investig Drugs. 2018;27(1):125-133.
    • Haase VH. Hemodial Int. 2017;21:S110–S124.
    • EVRENZO SmPC.
    • Akizawa T et al. J Am Soc Nephrol. 2020;31:1628-1639.

  • Why EVRENZO?

    A first-in-class1 treatment for anaemia of CKD

    Innovation

    • Anaemia of CKD is complex and multi-causal in nature2-4
    • By stimulating a coordinated erythropoietic response, EVRENZO can help patients achieve and maintain Hb levels within the desired target range5

    Confidence

    • EVRENZO achieved and maintained target Hb levels (10-12 g/dL) irrespective of dialysis status5
      • In patients not on dialysis, EVRENZO was statistically superior to placebo (p<0.0001) and non-inferior to ESA (p=0.844)5
      • In patients just started on dialysis, EVRENZO was non-inferior in Hb correction from baseline (95% CI; 0.28 [0.110, 0.451]) and maintenance (95% CI; 0.30 [0.228, 0.373]) compared with ESA5

    • The safety profile of EVRENZO was comparable to that of ESAs,5-9 and AEs were consistent with those commonly seen in patients with anaemia of CKD6-9

    Administration

    • EVRENZO offers oral administration with a three times weekly tablet5

    Examine the evidence
    See the patient perspective
    Listen to expert opinion

    AE, adverse event; CI, confidence interval; CKD, chronic kidney disease; Hb, haemoglobin; ESA, erythropoiesis-stimulating agent.

    References

    • Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.
    • Locatelli F et al. Am J Nephrol. 2017;45:187-199.
    • Babitt JL, Lin HY. J Am Soc Nephrol. 2012;23:1631–1634.
    • Fishbane S, Spinowitz B. Am J Kidney Dis. 2018;71:423–435.
    • EVRENZO SmPC.
    • Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.
    • Csiky B et al. Adv Ther. 2021;38(10):5361–5380.
    • Charytan C et al. Kidney Int Rep. 2021;6(7):1829–1839.
    • Akizawa T et al. J Am Soc Nephrol. 2020;31:1628-1639.



EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx (särskilt läkemedel), F

▼Detta läkemedel är föremål för utökad övervakning.

Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens tredje trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga (inklusive dödliga) kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Fertila kvinnor måste använda en högeffektiv preventivmetod under behandling och i minst en vecka efter sista dosen. Försiktighet gällande administrering krävs vid måttligt nedsatt leverfunktion och rekommenderas inte vid kraftigt nedsatt leverfunktion. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.

Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2024-09. 

För ytterligare information och förpackningar se www.fass.se.